Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Peter Silsbee who wrote (818)	6/11/1997 8:31:00 PM
From: John Metcalf	of 6136

83 cases of hyperglycemia of 150,000 US protease inhibitor users. Is that more or less than the rate for the general population? Do the cases occur disproportionately amongst the very sick, or throughout the user population? Is hyperglycemia linked to or aggravated by fasting dosages and large intakes of water? This is a very early indication of a manageable side effect, with many questions yet to be answered. An analyst quoted in the news story, Hemant Shah, said that hyperglycemia labeling would not put a dent in the PI market. Hyperglycemia is manageable; HIV is not manageable without PI's.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next